Last reviewed · How we verify

The Medicines Company — Portfolio Competitive Intelligence Brief

The Medicines Company pipeline: 1 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Placebo (D5W) Placebo (D5W) marketed
Angiomax (bivalirudin) Angiomax (bivalirudin) phase 3 Direct thrombin inhibitor Thrombin (Factor IIa) Cardiovascular
Standard of Care IV antihypertensive Standard of Care IV antihypertensive phase 3 ACE inhibitor AT1 receptor Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  2. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  3. Ain Shams University · 1 shared drug class
  4. Bayer · 1 shared drug class
  5. Beijing Tide Pharmaceutical Co., Ltd · 1 shared drug class
  6. Bioprojet · 1 shared drug class
  7. Boehringer Ingelheim · 1 shared drug class
  8. Ace Cells Lab Limited · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for The Medicines Company:

Cite this brief

Drug Landscape (2026). The Medicines Company — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/the-medicines-company. Accessed 2026-05-16.

Related